These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27994897)

  • 1. Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.
    Sinnecker T; Othman J; Kühl M; Metz I; Niendorf T; Kunkel A; Paul F; Wuerfel J; Faiss J
    Case Rep Neurol Med; 2016; 2016():5876798. PubMed ID: 27994897
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.
    Mickeviciene D; Baltusiene A; Afanasjeva B; Afanasjevas D; Gleizniene R; Rastenyte D; Berger JR
    BMC Neurol; 2022 Aug; 22(1):306. PubMed ID: 35986243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
    PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod.
    Piñar Morales R; Carrasco Garcia M; Gutierrez-Rojas L; Barrero Hernández FJ
    Case Rep Neurol; 2022; 14(1):38-43. PubMed ID: 35350291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
    Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
    Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
    Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
    Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
    BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
    Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A
    J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.
    Killestein J; Vennegoor A; van Golde AE; Bourez RL; Wijlens ML; Wattjes MP
    Case Rep Neurol Med; 2014; 2014():307872. PubMed ID: 25506447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Pitarokoili K; Hellwig K; Lukas C; Gold R
    Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.